WHWK

Whitehawk Therapeutics Inc (NASDAQ:WHWK) is a clinical-stage biopharmaceutical company that underwent a significant strategic transformation in 2024. Originally founded as Aadi Biosciences and going public in 2017, the company initially focused on developing precision therapies for genetically-defined cancers, particularly through its drug FYARRO for rare sarcomas. In late 2024, the company rebranded to Whitehawk Therapeutics and pivoted its strategy to focus on developing advanced antibody-drug conjugates (ADCs) for cancer treatment, while divesting its original FYARRO asset to Kaken Pharmaceuticals.